Chapter 6 120 Table 1. Baseline characteristics of the study participants. All participants (n=164) Magnesium citrate (n=46) Magnesium oxide (n=46) Magnesium sulphate (n=46) Placebo (n=26) Demographics Age, years 63.2 ± 6.8 64.1 ± 6.1 63.2 ± 6.7 62.0 ± 6.9 63.8 ± 7.8 Women, n (%) 104 (63.4) 31 (67.4) 29 (63.0) 30 (65.2) 14 (53.8) Caucasians, n (%) 162 (98.8) 45 (97.8) 46 (100) 45 (97.8) 25 (100) Body composition Weight, kg 85.0 ± 12.0 85.6 ± 13.0 82.8 ± 12.1 86.2 ± 11.8 85.6 ± 10.3 BMI, kg/m2 28.1 ± 2.8 28.7 ± 3.4 27.5 ± 2.1 28.4 ± 2.9 27.8 ± 2.4 Waist circumference, cm 95 ± 9 97 ± 10 94 ± 10 96 ± 9 96 ± 8 Males, cm 102 ± 8 104 ± 9 101 ± 9 101 ± 9 101 ± 7 Females, cm 92 ± 8 93 ± 8 89 ± 8 93 ± 9 92 ± 7 Hip circumference, cm 107 ± 7 110 ± 8 106 ± 6 107 ± 7 107 ± 5 Total body fat, (%) 35.3 ± 7.6 37.0 ± 8.0 34.2 ± 6.7 35.7 ± 8.3 33.8 ± 7.1 Males, cm 27.0 ± 3.9 27.7 ± 4.6 26.9 ± 4.0 26.0 ± 3.2 27.8 ± 3.9 Females, cm 40.3 ± 4.2 41.7 ± 4.5 38.7 ± 3.0 41.0 ± 4.3 39.3 ± 4.4 Medication usage Antihypertensive treatment, n (%) 25 (15.2) 8 (17.4) 4 (8.7) 7 (15.2) 6 (23.1) Beta-blockers, n (%) 9 (5.5) 4 (8.7) 0 (0) 4 (8.7) 1 (3.8) Calcium channel blockers, n (%) 4 (2.4) 2 (4.3) 0 (0) 1 (2.2) 1 (3.8) ACE-inhibitors, n (%) 9 (5.5) 3 (6.5) 2 (4.3) 1 (2.2) 3 (11.5) ARBs, n (%) 5 (3.0) 1 (2.2) 2 (4.3) 2 (4.3) 0 (0) Diuretics, n (%) 11 (6.7) 2 (4.3) 2 (4.3) 3 (6.5) 3 (11.5) Lipid-lowering treatment, n (%) 10 (6.1) 2 (4.3) 3 (6.5) 3 (6.5) 2 (7.7) Hypertension, n (%) 61 (37.2) 19 (41.3) 14 (30.4) 17 (37.0) 11 (42.3) Dyslipidemia, n (%) 47 (28.7) 11 (23.9) 12 (26.1) 16 (34.8) 8 (30.8) Total cholesterol, mmol/L 5.20 ± 0.82 5.23 ± 0.90 5.32 ± 0.84 5.08 ± 0.72 5.16 ± 0.79
RkJQdWJsaXNoZXIy MTk4NDMw